Contact
Innovation

Innovation

Research Areas

Prescription Drug
Medical Device
H&B (Health & Beauty)

R&D Vision and Accomplishments

R&D VisionGlobal Leadership in Medical Aesthetic and Pharmaceutical Fields

The Global Leader in Medical Aesthetics

We lead the global medical aesthetics market through a world-class portfolio of botulinum toxins, hyaluronic acid fillers, and injections for submental fat reduction, all with proven efficacy and safety.

Global Biotech Company

Driven by our proven R&D infrastructure and technical expertise, we are fully committed to developing innovative medicines that enhance human health and well-being.

R&D Accomplishments

The World’s Only Independent Developer of Three Distinct Botulinum Toxin Products

Global Leadership in HA Fillers Powered by Advanced Proprietary Technology

World's First to Develop Cholic Acid-based Injection for Submental Fat Reduction

Ratio of R&D Investment to Sales

2021년

14%

2022년

20%

2023년

25%

2024년

17%

2025년

19%

Pipeline

R&D is a starting point of drug development, commercialization and a locomotive in realizing continuous growth.

To stay true to our identity as an R&D-based biopharmaceutical company, Medytox invests more than 15% of total sales in R&D. With the Gwanggyo R&D Center, established with a one-stop system to conduct all drug development processes except clinical trials, we are developing biopharmaceuticals that will pioneer the global market.

Neuronox®

Category

Biopharmaceutical

Product Group

Botulinum Toxin Type A

Indication

Benign Essential Blepharospasm

Equinus deformity associated with spasticity in pediatric cerebral palsy patients

Glabellar Lines

Muscle Stiffness, Post-stroke Upper Limb Spasticity

Discovery
Nonclinical Study
Phase 1
Phase 2
Phase 3
Approval
Launch

INNOTOX®

Category

Biopharmaceutical

Product Group

Botulinum Toxin Type A

Indication

Glabellar Lines

Discovery
Nonclinical Study
Phase 1
Phase 2
Phase 3
Approval
Launch

CORETOX®

Category

Biopharmaceutical

Product Group

Botulinum Toxin Type A (150 kDa)

Indication

Glabellar Lines

Discovery
Nonclinical Study
Phase 1
Phase 2
Phase 3
Approval
Launch

NUVIJU®

Category

Biopharmaceutical

Product Group

Injectable Adipocytolytic Agent (Cholic Acid)

Indication

Submental Fat Reduction

Discovery
Nonclinical Study
Phase 1
Phase 2
Phase 3
Approval
Launch

MT10109L

Category

Biopharmaceutical

Product Group

Botulinum Toxin Type A

Indication

Glabellar Lines

Lateral Canthal Lines

Discovery
Nonclinical Study
Phase 1
Phase 2
Phase 3
Approval
Launch

* Clinical studies completed in the US, Europe, and Canada

MT117

Category

Biopharmaceutical

Indication

Various Solid Cancers

Discovery
Nonclinical Study
Phase 1
Phase 2
Phase 3
Approval
Launch

MT122

Category

Biopharmaceutical

Indication

Immune Disorders

Discovery
Nonclinical Study
Phase 1
Phase 2
Phase 3
Approval
Launch

MT124

Category

Biopharmaceutical

Indication

Various Solid Cancers

Discovery
Nonclinical Study
Phase 1
Phase 2
Phase 3
Approval
Launch

MT133

Category

Biopharmaceutical

Indication

Various Solid Cancers

Discovery
Nonclinical Study
Phase 1
Phase 2
Phase 3
Approval
Launch

MT951

Category

Biopharmaceutical

Indication

Aesthetic / Therapeutic

Discovery
Nonclinical Study
Phase 1
Phase 2
Phase 3
Approval
Launch

PF30

Category

Biopharmaceutical

Indication

Glabellar lines

Discovery
Nonclinical Study
Phase 1
Phase 2
Phase 3
Approval
Launch

Neuramis®

Category

Medical Device

Product Group

Hyaluronic Acid Filler

Intended Use

Deep Facial Wrinkles

Midface Volume*

*Neuramis® Volume Lidocaine*Neuramis® Heart

Discovery
Nonclinical Study
Clinical Trial
Approval
Launch

Atière®

Category

Medical Device

Product Group

Hyaluronic Acid Filler

Intended Use

Deep Facial Wrinkles

Midface Volume*

*Atière® Volume

Discovery
Nonclinical Study
Clinical Trial
Approval
Launch

Potenfill®

Category

Medical Device

Product Group

Hyaluronic Acid Filler

Intended Use

Temporary Penile Augmentation

Discovery
Nonclinical Study
Clinical Trial
Approval
Launch

MT942

Category

Medical Device

Intended Use

Prevention of Intrauterine Postoperative Adhesions

Discovery
Nonclinical Study
Clinical Trial
Approval
Launch

MTP51

Category

Medical Device

Intended Use

Skin Booster

Discovery
Nonclinical Study
Clinical Trial
Approval
Launch

MTP55

Category

Medical Device

Intended Use

Facial Wrinkles

Discovery
Nonclinical Study
Clinical Trial
Approval
Launch

MTP57

Category

Medical Device

Intended Use

Facial Wrinkles

Discovery
Nonclinical Study
Clinical Trial
Approval
Launch

MTP58

Category

Medical Device

Intended Use

Facial Wrinkles

Discovery
Nonclinical Study
Clinical Trial
Approval
Launch

MTP59

Category

Medical Device

Intended Use

Facial Wrinkles

Discovery
Nonclinical Study
Clinical Trial
Approval
Launch

LactiPLAN®

Category

Probiotics

Functionality

May Help Reduce Body Fat

Discovery
Nonclinical Study
Clinical Trial
Approval
Launch

Khan’s Morning®

Category

Food

Discovery
Nonclinical Study
Clinical Trial
Launch